L Lisata Therapeutics
L
Suletud
3.16 2.6
Ülevaade
Aktsiahinna muutus
24h
Min
3.12
Max
3.17
Sissetulek | 1.3M -3M |
|---|---|
Müük | 100K 100K |
Kasumimarginaal | -2,954 |
Töötajad | 21 |
Järgmine tulemuste avaldamine | 6. aug 2026 |
|---|
Turukapital | -16M 24M |
|---|---|
Eelmine avamishind | 0.56 |
Eelmine sulgemishind | 3.16 |
Lisata Therapeutics Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Lisata Therapeutics Prognoos
Finantsandmed
Müügi- ja halduskulud
Maksueelne kasum
Müük
Ärikasum
$
Ettevõttest Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.